Literature DB >> 8664196

A phase II study of Tomudex in relapsed epithelial ovarian cancer.

M E Gore1, H M Earl, J Cassidy, M Tattersall, J Mansi, L Seymour, M Azab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8664196     DOI： 10.1093/oxfordjournals.annonc.a059291

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).

Authors:  Georg A Bjarnason; Danielle Charpentier; Ralph Wong; Rakesh Goel; Lynn Douglas; Wendy Walsh; Sarah Matthews; Susan Dent; Lesley Seymour; Eric Winquist
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

2.  A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies.

Authors:  T Benepal; A Jackman; L Pyle; S Bate; A Hardcastle; W Aherne; F Mitchell; L Simmons; R Ruddle; F Raynaud; M Gore
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

3.  A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.

Authors:  M M Eatock; D A Anthony; M El-Abassi; P Wilson; J Paul; M Smith; M Soukop; T R Evans
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

4.  Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).

Authors:  I Judson; T Maughan; P Beale; J Primrose; P Hoskin; J Hanwell; C Berry; M Walker; F Sutcliffe
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.